{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178978","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.537303+00:00","generated_at":"2026-05-17T14:36:40.763667+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025","bullets":["Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.","Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.","Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.","New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.","New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178978","json":"https://secwatch.observer/filing/0001193125-25-178978.json","markdown":"https://secwatch.observer/filing/0001193125-25-178978.md","text":"https://secwatch.observer/filing/0001193125-25-178978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/0001193125-25-178978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/okur-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:36:40.763667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}